The efficacy of amantadine in the symptomatic treatment of patients with Parkinson's
disease, discovered serendipitously more than 50 years ago, has stood the test of time and …

Parkinson's disease (PD) is usually characterized by cardinal motor impairments. However,
a range of non-motor symptoms precede the motor-phase and are major determinants for …

Parkinson's Disease (PD) is the second most common neurodegenerative disease in the
elderly population, with a higher prevalence in men, independent of race and social class; it …

Parkinson's disease (PD) is a complex neurological disorder classically characterized by
impairments in motor system function associated with loss of dopaminergic neurons in the …

It is well-recognized that the gut microbiota (GM) is crucial for gut function, metabolism, and
energy cycles. The GM also has effects on neurological outcomes via many mechanisms …

The relative importance of antimuscarinic anticholinergic medications for Parkinson's
disease (PD) declined after the introduction of levodopa, such that anticholinergic …

Introduction There is currently a resurgence of levodopa as the initial treatment of choice for
most patients with Parkinson's disease, albeit at lower doses than previously used. The …

Parkinson's disease (PD) is the second common age-related neurodegenerative disease. It
is characterized by control loss of voluntary movements control, resting tremor, postural …

Hippocampal lesions are a defining pathology of Alzheimer's disease (AD). However, the
molecular mechanisms that underlie hippocampal synaptic injury in AD have not been fully …

Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be
difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation …